利妥昔单抗联合CHOP方案对非霍奇金淋巴瘤免疫功能、补体水平的影响

Effects of Rituximab Combined with CHOP Regimen on Immune Func⁃tion and Complement Level in Non-Hodgkin's Lymphoma

目的探讨利妥昔单抗联合CHOP方案对非霍奇金淋巴瘤免疫功能、补体水平的影响。方法选取2020年1-12月潍坊市中医院和潍坊医学院附属医院收治的非霍奇金淋巴瘤患者80例为研究对象,按照随机数字表法分为两组,各40例。对照组实施CHOP化疗方案,观察组则在CHOP化疗方案的基础上联合应用利妥昔单抗。比较两组治疗后体液免疫指标、血清补体C3、C4及血管生长因子水平变化,统计两组不良反应和临床效果。结果治疗后观察组IgM、IgG和IgA水平分别为(1.8±0.2)、(8.6±1.2)、(4.1±1.2)mg/L,均高于对照组,差异有统计学意义(t=11.180、2.951、10.000,P<0.05),治疗后观察组血清补体C3、C4及血管生长因子水平分别为(0.8±0.1)g/L、(0.3±0.1)g/L、(68.5±3.9)ng/L,均低于对照组,差异有统计学意义(t=8.944、8.944、18.923,P<0.05),观察组发生消化道不适、骨髓抑制、脱发和肝肾功能损伤的比例分别为1例(2.5%)、2例(5.0%)、1例(2.5%)、3例(7.5%),均显著低于对照组,差异有统计学意义(χ^(2)=8.538、7.440、11.114、7.813,P<0.05),观察组总有效率为97.5%,高于对照组的67.5%,差异有统计学意义(χ^(2)=12.468,P<0.05)。结论利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤,可有效地改善机体免疫能力,降低补体水平,抑制血管生长,减少并发症,提高临床治疗效果。

Objective To investigate the effect of rituximab combined with CHOP regimen on the immune function and complement level of non-Hodgkin's lymphoma.Methods A total of 80 patients with non-Hodgkin lymphoma who were admitted to Weifang Hospital of Traditional Chinese Medicine and the Affiliated Hospital of Weifang Medi⁃cal College from January to December 2020 were selected as the research subjects.According to the random number table method,they were divided into two groups,each with 40 cases.The control group was given CHOP chemo⁃therapy,while the observation group was given rituximab on the basis of CHOP chemotherapy.The changes of hu⁃moral immune indexes,serum complement C3,C4 and vascular growth factor levels after treatment were compared between the two groups.The adverse reactions and clinical effects of the two groups were compared.Results After treatment,the levels of IgM,IgG and IgA in the observation group were(1.8±0.2)mg/L,(8.6±1.2)mg/L a n d(4.1±1.2)mg/L,which were higher than those in the control group,and the difference was statistically significant(t=11.180,2.951,10.000,P<0.05).After treatment,the serum levels of complement C3,C4 and vascular growth factor in the observation group were(0.8±0.1)g/L,(0.3±0.1)g/L and(68.5±3.9)ng/L,respectively,were lower than the con⁃trol group,and the difference was statistically significant(t=8.944,8.944,18.923,P<0.05).The proportions of diges⁃tive tract discomfort,bone marrow suppression,hair loss and liver and kidney function damage in the observation group were 1 case(2.5%),2 cases(5.0%),1 case(2.5%)and 3 cases(7.5%),respectively,were significantly lower than the control group,and the difference was statistically significant(χ^(2)=8.538,7.440,11.114,7.813,P<0.05).The total effective rate in the observation group was 97.5% higher than that in the control group(67.5%),and the differ⁃ence was statistically significant(χ^(2)=12.468,P<0.05).Conclusion Rituximab combined with CHOP regimen in the treatment of non-Hodgkin's lymphoma can effectively improve the body's immunity,reduce the level of complement,inhibit the growth of blood vessels,reduce complications,and improve the clinical treatment effect.